What Happened
A federal judge on Monday declined to block Eli Lilly's television advertising for its obesity and diabetes medicines, rejecting Novo Nordisk's request for a preliminary injunction in a false-advertising case that has become the most visible legal front in the two companies' competition for the weight-loss market.
Judge Zahid Quraishi of the U.S. District Court in Trenton, New Jersey, issued a 25-page decision following a two-day hearing in late August. He found that Novo Nordisk had not shown the kind of irreparable harm that justifies emergency relief before trial. Lilly's campaigns, he wrote, had at most a negligible market impact between April and July, a stretch in which prescriptions for Novo Nordisk's products stayed stable. Money damages, the judge added, could compensate Novo for any "nontrivial harm" if it ultimately prevails.
Quraishi described Novo Nordisk's showing on a "very preliminary record" as less than persuasive, but he did not decide whether the advertisements are in fact false or misleading.
Novo Nordisk sued in July under federal and state false-advertising and unfair-competition law. Its central allegation is that Lilly compared higher doses of Zepbound and Mounjaro with lower doses of Wegovy and Ozempic. One commercial at issue states that people using Zepbound lost an average of 50 pounds while people using Wegovy lost 33 pounds.
Novo Nordisk said it was disappointed and stressed that the ruling did not resolve the underlying question. Lilly said it was pleased, and continues to deny wrongdoing.
Who Is Affected
- Patients and prescribers who weigh comparative claims in direct-to-consumer advertising when choosing between incretin therapies.
- Compounding pharmacies and gray-market sellers, whose marketing has come under separate scrutiny and who often repeat headline weight-loss figures without trial context.
- Peptide researchers and suppliers, because dose-matched comparisons are the difference between a valid efficacy claim and a misleading one.
Timeline
- July 21, 2026: Novo Nordisk sues Eli Lilly over comparative advertising.
- July 24, 2026: Novo seeks a preliminary injunction; Lilly denies wrongdoing and says it will defend its campaigns.
- Late August 2026: Two-day evidentiary hearing before Judge Quraishi.
- October 26, 2026: Injunction denied; the case proceeds on the merits.
- Next: discovery, a merits ruling on falsity, and Novo's requests for corrective advertising and damages.
What This Means for Researchers
Two lessons carry beyond this courtroom. First, an advertising claim is not clinical evidence. A 50-pound versus 33-pound comparison drawn from different trials, at different doses, in different populations says little about how two molecules perform under matched conditions. Second, the denial of an injunction is a procedural finding about harm, not an endorsement of the advertisements. The falsity question remains open.
For anyone reading trial data, the practical test is whether groups were dose-matched, whether discontinuations were counted, and whether the analysis assumed patients stayed on treatment.
How to Verify Your Peptides
Comparative marketing is a poor substitute for batch documentation. If you are evaluating a research peptide, start with how our testing works, then review the difference between HPLC purity and LC-MS identity testing. A certificate of analysis that reports identity, purity, and fill weight from an independent laboratory is the only claim that attaches to the vial in your hand.
Safe Alternatives
For approved, regulated options, review the prescribing information for tirzepatide and semaglutide, and compare suppliers with published third-party testing on our vendor directory. Our peptide library indexes the published literature behind each compound.
Sources
Industry reports; court filings and rulings; company statements.